Webinar: Mastering Translational Medicine in Clinical Trials
Now available on-demand
Hosted by: John Carroll, Editor, FierceBiotech
Much of the value in translational medicine is gained during early human studies, when key insights are gleaned in clinical trials which can inform and mold a program as it advances.
FierceBiotech invites you to join us on November 8th at 11 a.m. EST as three clinical trial experts discuss how to craft a cost-efficient study that creates a strong foundation for later-stage trial work. Topics will include potential use of biomarkers, dosing strategies, patient stratification, companion diagnostics and adaptive design methods.
Jared Gollob, M.D., Vice President, Clinical Research, Alnylam Dr. Gollob joined Alnylam in 2007 and has been responsible for management of the clinical development organization, in addition to serving in a program leadership role for the company's ALN-VSP program.
Dr. Hubert Chen, Vice President, Clinical Development, Aileron Hubert Chen leads the clinical development of our endocrine and metabolic program, ALRN-5281. Dr. Chen joined Aileron from Regulus Therapeutics, where he served as Vice President of Translational Medicine and was responsible for the development of microRNA-based medicines.
Karen Cornelissen, BSc PhD, Scientific Director, Covance Karen Cornelissen is currently the Scientific Director, at Covance Clinical Research Unit in Leeds, UK. As part of this role, Karen advises on study design and subsequent data interpretation, which draws upon her experience in analytical chemistry, drug metabolism and pharmacokinetics.